GILEAD SCIENCES, INC. Other Research and Development Expense
GILEAD SCIENCES, INC. (GILD) reported Other Research and Development Expense of $126.00 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2019-05-08
- GILEAD SCIENCES, INC. other research and development expense for the quarter ending 2019-03-31 was $126.00M.
- GILEAD SCIENCES, INC. other research and development expense for the quarter ending 2018-12-31 was $118.00M.
- GILEAD SCIENCES, INC. other research and development expense for the quarter ending 2018-09-30 was $0.00.
- GILEAD SCIENCES, INC. other research and development expense for the quarter ending 2018-06-30 was $160.00M.
- GILEAD SCIENCES, INC. other research and development expense for fiscal 2018 was $278.00M.
| Period end | Other Research and Development Expense 3 month | Other Research and Development Expense 6 month | Other Research and Development Expense 9 month | Other Research and Development Expense 12 month |
|---|---|---|---|---|
| 2019-03-31 | $126.00M 10-Q · filed 2019-05-08 | $244.00M derived: sum of 2 quarters · filed 2019-05-08 | $244.00M derived: sum of 3 quarters · filed 2019-05-08 | $404.00M derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-12-31 | $118.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $118.00M derived: sum of 2 quarters · filed 2019-02-26 | $278.00M derived: sum of 3 quarters · filed 2019-02-26 | $278.00M 10-K · filed 2019-02-26 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $160.00M derived: sum of 2 quarters · filed 2018-11-06 | $160.00M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $160.00M 10-Q · filed 2018-08-06 | $160.00M 10-Q · filed 2018-08-06 | ||
| 2018-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |